Razai
Ali Razai, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20100166773 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS - This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 07-01-2010 |
20140105910 | Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins - This invention provides antibodies that specifically bind to and typically neutralize | 04-17-2014 |
Ali Razai, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20090324606 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS - This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 12-31-2009 |
Ali Razai, La Jolla, CA US
Patent application number | Description | Published |
---|---|---|
20110171235 | THERAPEUTIC MONOCLONAL ANTIBODIES THAT NEUTRALIZE BOTULINUM NEUROTOXINS - This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 07-14-2011 |
20120177663 | Therapeutic Monoclonal Antibodies that Neutralize Botulinum Neurotoxins - This invention provides antibodies that specifically bind to and neutralize botulinum neurotoxin type A (BoNT/A) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism. | 07-12-2012 |
Ali R. Razai, Columbus, OH US
Patent application number | Description | Published |
---|---|---|
20150367128 | APPARATUS, SYSTEMS, AND METHODS FOR TREATING BODY ORGAN AGING - One aspect of the present disclosure relates to a method for treating body organ aging in a mammal. One step of the method includes identifying at least one target organ in need of a therapy signal. Next, a therapy delivery device is placed into electrical communication with an autonomic nervous system (ANS) nerve target and/or a central nervous system (CNS) nerve target associated with the at least one target organ. The therapy delivery device is then activated to deliver the therapy signal to the ANS nerve target and/or the CNS nerve target in an amount and for a time sufficient to effect a change in sympathetic and/or parasympathetic activity associated with the at least one target organ. | 12-24-2015 |
Amir Razai, La Jolla, CA US
Patent application number | Description | Published |
---|---|---|
20130224188 | CD47 Antibodies and Methods of Use Thereof - This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics. | 08-29-2013 |
20140140989 | Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof - This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, red blood cell depletion, amenia, and/or platelet depletion, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics. | 05-22-2014 |
Amir Razai, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20150238604 | CD47 ANTIBODIES AND METHODS OF USE THEREOF - This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics. | 08-27-2015 |